Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Patterns and predictors of relapse in primary gastric diffuse large B cell lymphoma (DLBCL) were variably reported. Our study aims to evaluate the patterns and predictors of relapse in early-stage gastric DLBCL treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (RCHOP).
Methods: From 2005 to 2019, the medical records of 72 patients with stage I or stage II gastric DLBCL treated with six cycles of RCHOP without radiotherapy were reviewed. Different variables were correlated with progression free survival (PFS), overall survival (OS), and local relapse free survival (LRFS).
Results: 64 (88.1%) patients achieved a complete response (CR), while 8 (11.9%) had refractory disease. After CR, 9 (14%) patients relapsed; 7 (78%) relapses were loco-regional. Abnormal LDH ( = 0.028), H. pylori negative ( = 0.032) and, stage adjusted international prognostic index (sa-IPI) > 1 ( = 0.013) correlated with loco-regional failure. The 5-year PFS, OS, and LRFS were 74.8%, 75.3%, and 87.5%, respectively, after a median follow-up of 58 (range: 6-185) months. The median time to progression or relapse was 9 months (range: 5-54 months). In multivariate analysis, a sa-IPI >1 (HR: 3.56, CI: 1.35-8.8, = 0.01) was associated with PFS while low albumin (HR: 8.85, CI: 1.09-71.4, = 0.041) was associated with worse OS. None of the variables were associated with LRFS.
Conclusion: Treatment of primary gastric DLBCL with RCHOP results in a high CR rate. The majority of treatment failures were loco-regional. Sa-IPI and H. pylori status may be used to identify patients who may benefit from combined modality treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/16078454.2023.2198898 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report.
Cancer Rep (Hoboken)
September 2025
Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Background: Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies.
View Article and Find Full Text PDFIntrapatient genomic divergence across multiple primary tumors in young Korean patients.
Korean J Clin Oncol
August 2025
Department of Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
Purpose: Multiple primary tumors arising in the same individual pose challenges for precision oncology, particularly in the context of hereditary cancer syndromes such as Lynch syndrome. While these tumors may originate from a shared germline predisposition, it remains unclear whether they also share somatic alterations that could be therapeutically exploited. This study aimed to characterize the extent of somatic genomic overlap between synchronous or metachronous gastric and colorectal cancers within young Korean patients.
View Article and Find Full Text PDFChronic kidney disease and incident cancer risk: an individual participant data meta-analysis.
Br J Cancer
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results.
Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer.
The utility of artificial intelligence in gastrointestinal oncology: A systematic review of randomized controlled trials.
Cancer
September 2025
Section of Hematology and Oncology, Department of Medicine, University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
In the field of gastrointestinal oncology, the development of novel artificial intelligence (AI) processes may help with multiple aspects of cancer care delivery. However, a comprehensive understanding of the current utility of AI in gastrointestinal oncology is lacking. The authors conducted searches in the following databases: MEDLINE (Ovid), Embase (Ovid), and CINAHL (Cumulative Index of Nursing and Allied Health) Ultimate (EBSCO).
View Article and Find Full Text PDFScreening and eradication of or gastric cancer prevention: Taipei Global Consensus II.
Gut
September 2025
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Objective: To convene a global consensus on () screening and eradication strategies for gastric cancer prevention, identify key knowledge gaps and outline future research directions.
Methods: 32 experts from 12 countries developed and refined consensus statements on management, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess evidence and the Delphi method to achieve ≥80% agreement.
Results: Consensus was achieved on 28 statements.